214 related articles for article (PubMed ID: 35628622)
1. In-Silico Selection of Aptamer Targeting SARS-CoV-2 Spike Protein.
Lin YC; Chen WY; Hwu ET; Hu WP
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628622
[TBL] [Abstract][Full Text] [Related]
2.
Chen Y; Yang X; Liu J; Zhang D; He J; Tang L; Li J; Xiang Q
Nucleosides Nucleotides Nucleic Acids; 2023; 42(2):105-118. PubMed ID: 35949145
[TBL] [Abstract][Full Text] [Related]
3. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach.
Silwal AP; Thennakoon SKS; Arya SP; Postema RM; Jahan R; Phuoc CMT; Tan X
Theranostics; 2022; 12(12):5522-5536. PubMed ID: 35910791
[No Abstract] [Full Text] [Related]
4. Preventive treatment of coronavirus disease-2019 virus using coronavirus disease-2019-receptor-binding domain 1C aptamer by suppress the expression of angiotensin-converting enzyme 2 receptor.
Hameed NS; Arif IS; Al-Sudani BT
J Adv Pharm Technol Res; 2023; 14(3):185-190. PubMed ID: 37692001
[TBL] [Abstract][Full Text] [Related]
5. A high-affinity aptamer with base-appended base-modified DNA bound to isolated authentic SARS-CoV-2 strains wild-type and B.1.617.2 (delta variant).
Minagawa H; Sawa H; Fujita T; Kato S; Inaguma A; Hirose M; Orba Y; Sasaki M; Tabata K; Nomura N; Shingai M; Suzuki Y; Horii K
Biochem Biophys Res Commun; 2022 Jul; 614():207-212. PubMed ID: 35617879
[TBL] [Abstract][Full Text] [Related]
6. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
Saify Nabiabad H; Amini M; Demirdas S
Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
[TBL] [Abstract][Full Text] [Related]
7. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
Devi A; Chaitanya NSN
Mol Divers; 2022 Feb; 26(1):157-169. PubMed ID: 33389440
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Song Y; Song J; Wei X; Huang M; Sun M; Zhu L; Lin B; Shen H; Zhu Z; Yang C
Anal Chem; 2020 Jul; 92(14):9895-9900. PubMed ID: 32551560
[TBL] [Abstract][Full Text] [Related]
9. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
[TBL] [Abstract][Full Text] [Related]
10. RaptGen-Assisted Generation of an RNA/DNA Hybrid Aptamer against SARS-CoV-2 Spike Protein.
Adachi T; Nakamura S; Michishita A; Kawahara D; Yamamoto M; Hamada M; Nakamura Y
Biochemistry; 2024 Apr; 63(7):906-912. PubMed ID: 38457656
[TBL] [Abstract][Full Text] [Related]
11. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
12.
Morena F; Argentati C; Tortorella I; Emiliani C; Martino S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206794
[TBL] [Abstract][Full Text] [Related]
13. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction.
Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR
BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443
[TBL] [Abstract][Full Text] [Related]
14.
Rout J; Swain BC; Tripathy U
J Biomol Struct Dyn; 2022 Feb; 40(2):860-874. PubMed ID: 32938313
[TBL] [Abstract][Full Text] [Related]
15. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
Peters MH; Bastidas O; Kokron DS; Henze CE
PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: docking-based virtual screening and molecular dynamics study to identify potential SARS-CoV-2 spike protein inhibitors from plant-based phenolic compounds.
Moradkhani S; Farmani A; Saidijam M; Taherkhani A
Acta Virol; 2021; 65(3):288-302. PubMed ID: 34565157
[TBL] [Abstract][Full Text] [Related]
17. DNA aptamer selection for SARS-CoV-2 spike glycoprotein detection.
Martínez-Roque MA; Franco-Urquijo PA; García-Velásquez VM; Choukeife M; Mayer G; Molina-Ramírez SR; Figueroa-Miranda G; Mayer D; Alvarez-Salas LM
Anal Biochem; 2022 May; 645():114633. PubMed ID: 35247355
[TBL] [Abstract][Full Text] [Related]
18. Enzyme linked oligonucleotide assay for the sensitive detection of SARS-CoV-2 variants.
Shola David M; Kanayeva D
Front Cell Infect Microbiol; 2022; 12():1017542. PubMed ID: 36250054
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism of Interaction between DNA Aptamer and Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus 2 Variants Revealed by Steered Molecular Dynamics Simulations.
Ding X; Xu C; Zheng B; Yu H; Zheng P
Molecules; 2024 May; 29(10):. PubMed ID: 38792076
[TBL] [Abstract][Full Text] [Related]
20. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
Ibrahim IM; Elfiky AA; Elgohary AM
Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
